LPA and atherosclerosis: The emergence of RNA-based therapeutics aimed at potently reducing Lp(a) levels has identified Lp(a) as a key residual risk factor to focus on in the effort to combat lipid-driven atherosclerotic cardiovascular disease (ASCVD) risk.